Morgan Stanley analyst Erin Wright raised the firm’s price target on BrightSpring Health (BTSG) to $20 from $19 and keeps an Overweight rating on the shares. Diversified Managed Care “woefully underperformed” in 2024 and while uncertainty is pressuring sentiment, the firm sees “opportunities in a friendlier policy backdrop,” the analyst tells investors in a 2025 outlook note on the healthcare services group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health initiated with an Outperform at CJS Securities
- BrightSpring Health Services Achieves Major Loan Refinancing
- BrightSpring Health price target raised to $21 from $19 at BofA
- BrightSpring Health price target raised to $21 from $17 at Wells Fargo
- BrightSpring Health price target raised to $20 from $13 at Deutsche Bank